<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>https://www.dottnet.it/articolo/32544028/viatris-acquisisce-pacira-per-1-65-miliardi-rafforzato-il-portafoglio-di-terapie-non-oppioidi-per-il-dolore</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Viatris acquisisce Pacira per 1,65 miliardi: rafforzato il portafoglio di terapie non oppioidi per il dolore</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544028-56865.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544029/febbre-e-dolore-nel-bambino-con-malattia-cronica-come-scegliere-l-antipiretico-piu-sicuro</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Febbre e dolore nel bambino con malattia cronica: come scegliere l&#39;antipiretico più sicuro</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544029-djvmar1012-10.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32543837/dolore-neuropatico-orofacciale-rtms-e-tdcs-mostrano-risultati-promettenti</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Dolore neuropatico orofacciale, rTMS e tDCS mostrano risultati promettenti</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32543837-djvmar972-09.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544031/boston-scientific-porta-j-j-in-tribunale-al-centro-il-dispositivo-hotwire-per-procedure-cardiache</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Boston Scientific porta J&amp;J in tribunale: al centro il dispositivo Hotwire per procedure cardiache</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544031-4452392.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544033/fimmg-cosa-aspettarsi-da-biancalani-la-lezione-della-toscana</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>FIMMG, cosa aspettarsi da Biancalani: la lezione della Toscana</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544033-medici4.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544034/sindrome-di-hunter-italfarmaco-punta-su-jr-141-accordo-esclusivo-per-stati-uniti-europa-e-america-latina</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Sindrome di Hunter, Italfarmaco punta su JR-141: accordo esclusivo per Stati Uniti, Europa e America Latina</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544034-3818556.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544036/nelle-cellule-del-sangue-il-segreto-di-come-stiamo-invecchiando-scoperta-una-possibile-spia-della-salute-futura</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Nelle cellule del sangue il segreto di come stiamo invecchiando: scoperta una possibile spia della salute futura</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544036-anteprimearticolidottnet-2026-10-12t112221718.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544035/non-solo-dimagrimento-il-nuovo-farmaco-contro-l-obesita-riduce-dolore-apnee-notturne-e-infiammazione</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Non solo dimagrimento: il nuovo farmaco contro l’obesità riduce dolore, apnee notturne e infiammazione</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544035-anteprimearticolidottnet-2026-10-12t111609294.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544037/responsabilita-medica-la-riforma-arriva-alla-camera-le-novita</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Responsabilità medica, la riforma arriva alla Camera: le novità</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544037-professionisanitarie4.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544038/radioterapia-e-nuovi-farmaci-oncologici-a-firenze-una-consensus-internazionale-per-guidare-le-scelte-cliniche</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Radioterapia e nuovi farmaci oncologici: a Firenze una Consensus internazionale per guidare le scelte cliniche</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544038-consensu.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544039/salute-mentale-schillaci-rilancia-il-piano-fondi-e-sfide-aperte</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Salute mentale, Schillaci rilancia il Piano: fondi e sfide aperte</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544039-salutementale.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32543852/aifa-approva-9-nuove-rimborsabilita-mirdametinib-e-zanidatamab-per-malattie-rare-sette-estensioni-di-indicazione</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>AIFA approva 9 nuove rimborsabilità: mirdametinib e zanidatamab per malattie rare, sette estensioni di indicazione</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32543852-19197272.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544040/dipendenze-300mila-persone-assistite-ogni-anno-federserd-chiede-piu-risorse-e-servizi-territoriali-integrati</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Dipendenze, 300mila persone assistite ogni anno: FeDerSerD chiede più risorse e servizi territoriali integrati</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544040-fednaz26350x243.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544032/nasce-la-classe-c-nn-r-accesso-temporaneo-rimborsato-per-i-farmaci-innovativi-in-attesa-di-negoziazione-aifa</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Nasce la classe C(nn)-R: accesso temporaneo rimborsato per i farmaci innovativi in attesa di negoziazione AIFA</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544032-2010i121044isometricgastroenterologyset-01-03.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544030/mifepristone-revisione-fda-entro-marzo-2027-possibile-impatto-sulle-modalita-di-accesso</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Mifepristone, revisione FDA entro marzo 2027: possibile impatto sulle modalità di accesso</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544030-medium-shot-woman-crying.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544041/chirurgia-schillaci-120-milioni-l-anno-e-scudo-penale-per-i-medici</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Chirurgia, Schillaci: 120 milioni l&#39;anno e scudo penale per i medici</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544041-chirurgia.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544042/obesita-quasi-un-italiano-su-due-e-in-eccesso-di-peso-perche-stiamo-abbandonando-la-dieta-mediterranea</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Obesità, quasi un italiano su due è in eccesso di peso: perché stiamo abbandonando la Dieta Mediterranea</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544042-anteprimearticolidottnet-2026-10-12t144751356.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544043/ibsa-a-lodi-la-produzione-di-acido-ialuronico-punta-a-14-milioni-di-siringhe-l-anno</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>IBSA, a Lodi la produzione di acido ialuronico punta a 14 milioni di siringhe l’anno</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544043-close-up-syringe-with-vaccine1.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544044/carcinoma-del-colon-dmmr-la-fda-approva-atezolizumab-in-adiuvante</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Carcinoma del colon dMMR, la FDA approva atezolizumab in adiuvante</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544044-2304i105024sm005c13isometricgastroenterologist.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544045/dolore-neuropatico-dopo-lesione-midollare-una-nuova-strategia-di-neuromodulazione-per-una-complicanza-difficile-da-trattare</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Dolore neuropatico dopo lesione midollare, una nuova strategia di neuromodulazione per una complicanza difficile da trattare</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544045-patient-receiving-neurofeedback-therapy-improve-brain-function-treat-neurological-condition1.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544046/pensioni-enpam-a-novembre-aumenti-e-dieci-mesi-di-arretrati</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Pensioni Enpam, a novembre aumenti e dieci mesi di arretrati</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544046-pensione2.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544047/cinque-richieste-della-sir-alle-istituzioni-per-rilanciare-le-cure-nel-ssn</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Cinque richieste della SIR alle Istituzioni per rilanciare le cure nel SSN</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544047-reumatologi.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544048/intelligenza-artificiale-una-quota-dei-crediti-ecm-sara-dedicata-all-ia</loc>
  <lastmod>2026-10-12T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Intelligenza artificiale, una quota dei crediti ECM sarà dedicata all&#39;IA</news:title>
   <news:publication_date>2026-10-12</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544048-intelligenzaartificiale.jpg</image:loc>
  </image:image>
 </url>
</urlset>